Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Monday, September 17, 2007

TransMedics tackling the public market with IPO plan

TransMedics Inc., an Andover-based medical devices firm, wants to raise $86.3 million in an initial public offering, according to a U.S. Securities and Exchange Commission filing.

The firm said it would use the proceeds of an IPO to fund development and marketing of its Organ Care System, or OCS, designed to keep organs fresh before transplants.

The device was cleared for use in heart transplants in the European Union in 2006, and sales of the device began in European during the second quarter of 2007, according to the company. Still conducting studies to obtain U.S. clearance for the device, the company said it is also developing it for lung, liver and kidney transplants.

The company said it employs 40 workers in various roles related to the development of the transplant device. It reported a 2006 net loss of $17.6 million on no revenue.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Comments

Please Login/Register to post comments.

No comments have been added or approved.

On the MHT blog now

Women to Watch: What makes them special

By James M. Connolly Intelligence, dedicated, leader, innovative, hard-working — they’re all words associated with the 11 women recognized with the Mass High Tech Women to Watch awards this morning. But back at the office we were talking how commonly another word has to be applied to the 2010 honorees and their 60 predecessors. It’s their humility. It’s so striking. We at Mass High T...

Read More

Most Popular Stories
EmailedViewed
Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
FinanceFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio